CurrentCapital BluecrossPolicy AHS - T2015 - Prescription Medication and Illicit Drug Testing in the Outpatient Setting, 1 = Initial Presentation

Prescription Medication and Illicit Drug Testing in the Outpatient Setting

Coverage policy for presumptive and definitive outpatient drug testing (primarily urine/oral fluid) including indications, limitations, frequency, and reimbursement rules for patients receiving care in non-forensic outpatient settings.

Policy Summary

PayerCapital Bluecross

PolicyPrescription Medication and Illicit Drug Testing in the Outpatient Setting

Policy CodePolicy AHS - T2015 - Prescription Medication and Illicit Drug Testing in the Outpatient Setting, 1 = Initial Presentation

Change TypeNo material change

Effective Date06/06/2015

Next Review DateN/A

Key ActionConfirm positive point-of-care or unexpected immunoassay results with definitive laboratory testing (GC/MS or LC-MS/MS) before making major clinical decisions.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1-4/yrPresumptive testing frequency (COT)

up to 7Definitive test classes allowed

no>7-class definitive panels covered

urine/oral fluidCovered specimen types

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

~30+Procedure codes listed

Coverage Criteria

Presumptive Urine Screening (Covered)

Presumptive urine drug screening meets coverage when ANY of the following are met:

Presumptive Drug Screening Covered Indications: a) Assessment of individuals treated for chronic non-cancer pain when clinical evaluation (history/signs/symptoms) suggests non-prescribed or illegal substance use, including prior to initiating chronic opioid therapy and for routine monitoring with frequency based on documented risk (low: up to 1/yr; moderate: up to 2/yr; high: up to 4/yr).

Follow documentation and risk-assessment procedures; random testing intervals and drugs selected should be based on patient history and documented in the medical record.

Pregnancy and peripartum: b) Pregnant individuals at high risk for substance abuse when suspicion exists based on screening questions or PDMP information, as documented in the medical record.

Obstetric consent and state-law compliance recommended.

Newborns and birthing parent concerns: c) Newborns when there is a history of maternal substance abuse or altered/agitated maternal mental status during delivery.

Document maternal history in the record.

Transplant candidates: d) Candidates for organ transplant with a history of substance abuse to demonstrate abstinence prior to transplant.

Documentation of history and testing required.

Behavioral health and psychiatric indications: e) Individuals with suspected or diagnosed mental illness (e.g., anxiety disorders, schizophrenia, mood disorders, suicidal ideation, substance use disorder) where substance use could affect diagnosis or management.

Document clinical rationale.

ADHD and disruptive behavior disorders: f) Individuals with attention-deficit hyperactivity and disruptive behavior disorders when assessment for stimulant misuse is clinically indicated.

Document clinical rationale.

Cancer and seizure populations: g) Cancer patients on opioid pain medication and h) individuals with epilepsy when DOA testing is clinically indicated to inform safe treatment choices.

Consider drug interactions (e.g., cocaine with some antiepileptics).

Substance abuse treatment monitoring: i) Management and compliance monitoring of individuals in substance abuse treatment with random qualitative testing per documented abstinence intervals: 0–90 days: 1–2/week; >90 days: 1–3/month.see documented frequencies

Must be documented in the medical record; random testing recommended.

When substance abuse is in differential: j) When substance abuse is in the differential diagnosis of the presenting condition (e.g., acute psychosis, intoxication, unexplained medical presentation).

Use testing when results may affect management.

Definitive/Confirmatory Testing (Covered, limited)

Definitive (confirmatory) qualitative or quantitative testing MEETS COVERAGE CRITERIA when ALL of the following are true:

Definitive Testing Covered Conditions: - Laboratory-based definitive testing is specifically requested and is limited to panels of up to seven drug classes. - The treating physician documents the rationale in the patient's medical record. - At least one of the following indications is present: (a) discrepant presumptive screen versus medical history/clinical presentation/patient statement; (b) need for accurate, reliable results for diagnosis or monitoring of substance use disorder with abstinence-specific frequency rules; (c) monitoring individuals on opioid therapy to ensure adherence or detect non-prescribed opioids; (d) no adequate presumptive test exists or presumptive testing does not detect the specific drug/metabolite of interest (e.g., within amphetamine, barbiturate, benzodiazepine, tricyclic antidepressant, opiate/opioid classes, or novel/synthetic analogs); (e) need to definitively identify a specific drug within a large family; (f) need for a definitive concentration to guide management.up to 7 drug classes

Abstinence-specific definitive testing frequency: 0–30 days ≤1/week; 31–90 days 1–3/month (no more than 3/month); >90 days 1–3 every 3 months (no more than 3/3 months).

Not Medically Necessary / Not Covered

Not covered situations:

Not Covered Testing: - Laboratory definitive testing for panels larger than seven drug classes. - Confirmatory/definitive or presumptive testing performed using proprietary platforms/tests (e.g., CareView360) or other proprietary assays. - Specimen validity testing (e.g., urine specific gravity, creatinine, pH, oxidant levels, genetic identity testing). - All other situations not specifically addressed under the covered indications in this policy.

These situations do not meet coverage criteria and are not reimbursed.

Indications for DOA testing

Covered or clinically useful in specific contexts when results will affect management

Applicable clinical contexts: UDT is clinically useful for drug treatment programs, pain management monitoring, psychiatric evaluation when substance use is suspected, and pre-operative screening (e.g., prior to joint arthroplasty) when results may alter perioperative risk assessment or management.

Evidence supports algorithmic baseline testing and repeat monitoring to improve compliance in some cohorts.

Screening and confirmation

Testing methods and interpretation requirements

Recommended testing pathway: Initial presumptive immunoassay or point-of-care testing may be used for screening; positive or clinically discordant/ unexpected results should be confirmed by definitive laboratory methods (e.g., GC-MS or LC-MS/MS).

MS-based assays are considered gold standard; immunoassays have lower sensitivity/specificity and are subject to false positives/negatives and provider interpretation error.

Recommended testing practices and limitations

Guidance and recommended testing practices from reviewed organizations

Definitive testing recommended: Use definitive UDM testing (GC-MS, LC-MS, LC-MS/MS) as the preferred method for baseline assessment and ongoing monitoring in most patients on opioid therapy unless institutional or payer policy requires immunoassay.

Consensus guidance (Argoff et al.) and AACC recommend definitive testing when feasible.

Risk-stratified monitoring frequency: Perform baseline testing prior to initiating opioid therapy. Ongoing monitoring: at least annually for low-risk patients; two or more times per year for moderate-risk; three or more times per year for high-risk patients; increase frequency based on clinical judgment or aberrant behaviors.frequency tiers per risk level

CDC, Argoff consensus, and other specialty organizations provide similar tiered recommendations.

Use confirmatory testing when results will affect decisions: Confirmatory (definitive) testing should be used when results will inform major clinical or nonclinical decisions, to identify specific opioids/metabolites, or to resolve unexpected screening results.

Perioperative and chronic opioid therapy monitoring

Use of UDS for perioperative risk assessment and monitoring within chronic opioid therapy (COT)

Preoperative screening: Urine drug screening can detect unprescribed opioid use preoperatively and may be used for initial risk assessment prior to procedures such as joint arthroplasty, recognizing limitations in detection windows and lack of normalization for dose/duration.

Study data (Vopat et al.) support potential benefit for initial risk assessment.

Chronic opioid therapy monitoring: For patients on chronic opioid therapy, periodic and random urine drug screening is recommended, especially for high-risk patients or those with aberrant behaviors; clinicians should reassess pain, function, adverse events, and adherence regularly.

APS/AAPM guidance supports periodic monitoring and suggests random testing may be more informative than scheduled tests.

Risk-stratified UDT frequency and follow-up

Recommendations on frequency and use of UDT vary by guideline and should be risk-stratified; included examples:

Washington State AMDG guidance: Low-risk: up to once per year; Moderate-risk: up to two per year; High-risk: up to three to four tests per year; Aberrant behaviors: test at time of office visit.

AMDG guidance.

Texas Pain Society guidance: Low-risk: 1–2 tests/year; Moderate-risk: 3–4 tests/year; High-risk: 4/year or monthly, at every office visit, or every drug refill.

Texas Pain Society recommendations.

APS/AAPM monitoring frequency: For low-risk individuals, quarterly or semi-annual monitoring may be sufficient; random UDS may be preferred over scheduled testing.

APS/AAPM guidance.

ASAM testing intensity in SUD treatment:

Federal/OTP testing requirements

Federal and OTP-specific requirements

SAMHSA OTP admission testing: Test at minimum for opioids, methadone, amphetamines, cocaine, and benzodiazepines prior to admission to opioid treatment programs; include other drugs based on community patterns or medical indications.

SAMHSA certification requirements for OTPs.

HHS oral fluid and federal testing mandates: Federal workplace oral fluid specimens must be tested for marijuana and cocaine and may be tested for other Schedule I/II drugs and biomarkers per HHS guidelines; HHS-certified laboratories have restrictions on routine additional testing without prior authorization.

HHS federal workplace testing rules.

Interpretation and confirmatory testing guidance

Test selection and interpretation considerations

Quantification and interpretation: Quantitative results should not be used to determine adherence to a dosing regimen; quantification can aid interpretation in select circumstances (e.g., distinguishing ongoing excretion from cessation, variant metabolism) and lower limits of detection may improve detection of low-dose use.

ASAM and AACC guidance caution against routine reliance on quantification for adherence assessment.

Confirmatory testing: Definitive testing (GC/MS, LC-MS) should be used when clinicians need specific substance identification or when results will inform major clinical or legal decisions; immunoassays have specificity limitations and unexpected results warrant confirmatory testing.

ASAM and AACC recommend confirmatory testing in these situations.

Guideline-based indications

Testing is discussed by specialty organizations with condition-specific recommendations

Acute psychosis: Toxicology screens are indicated for acute onset or exacerbations of psychosis when exposure to drugs of abuse cannot otherwise be ruled out.

AACAP guidance.

Schizophrenia evaluation: Drug screening (urine and blood) should be sought during evaluations for schizophrenia because substance use is often under-recognized during acute episodes.

WFSBP guidance.

Status epilepticus and seizures: Toxicology testing may be considered in children with status epilepticus when no apparent etiology is identified.

AAN guidance.

Opioid therapy risk mitigation:

This policy explicitly excludes drug testing conducted for forensic or legally mandated purposes, employment-related testing (for example, commercial driver licensing or other job-related requirements), and drug testing performed as part of urgent or emergency care. These use cases are outside the scope of coverage criteria described here and should be managed according to applicable state and federal regulations and any separate employer or court-directed programs.

A multicenter retrospective review found routine acetaminophen or salicylate screening in psychiatric pre-admission to be of low clinical value; the authors concluded such testing was "unnecessary and wasteful." Routine screening for these agents in that context is not supported by this evidence.

The policy notes that quantitative urine testing should not be used solely to determine prescribed dosage adherence or exact dosing because interindividual variability in pharmacokinetics, pharmacodynamics, and pharmacogenetics limits correlation between measured concentrations and dose. Quantitative testing may be useful in select complex cases (e.g., suspected unusual metabolism or drug interactions), but it is not a reliable measure of routine dose compliance.

Reviewed guideline summaries show no universal consensus on urine drug testing frequency; recommendations vary across organizations. Some guidelines advise testing primarily for high-risk patients, while others leave testing frequency to clinician discretion or local policy, underscoring the need for risk-stratified approaches.

The American College of Obstetricians and Gynecologists (ACOG) observes that routine universal urine drug screening is controversial. ACOG recommends using validated verbal screening tools as part of comprehensive obstetric care and cautions against universal UDT as a standalone screen without appropriate consent and legal compliance.

Procedure and billing codes included in this Medical Policy are provided only as a general reference for the policy and its coverage discussions. The code lists may not be exhaustive and should not be interpreted as the sole authoritative billing resource.

The reference listings in this section do not state explicit coverage exclusions beyond those detailed in policy text; they are citations supporting the clinical and guideline context rather than a separate list of exclusions.

The policy identifies several testing approaches and platforms that do not meet coverage criteria, including proprietary assay platforms (for example, CareView360), specimen validity testing (urine specific gravity, creatinine, pH, oxidant testing, genetic identity verification), and laboratory definitive panels that exceed seven drug classes. Additionally, testing situations not expressly listed as covered are treated as not meeting coverage criteria.

For routine acute general clinical management, the document states that drugs-of-abuse (DOA) monitoring is of limited value for most patients and may not be necessary unless the results will meaningfully inform clinical decisions (for example, in pain management, SUD programs, or psychiatric evaluation). Use is recommended when testing results will affect management.

The policy reiterates that quantitative testing alone is not supported as a method to determine patient compliance with dosing regimens because concentrations correlate poorly with dose across individuals. Quantitative results may be informative for specialized clinical questions but should not be used in isolation to assess adherence.

ACOG guidance emphasizes that routine universal UDT for pregnant women is controversial and recommends validated verbal screening tools as the preferred initial approach. When UDT is used in pregnancy it should be performed with patient consent, legal awareness, and appropriate confirmatory testing as indicated.

The references compiled in support of this policy do not include explicit blanket statements labeling particular tests or circumstances as universally 'not medically necessary' beyond the policy's own stated coverage criteria; instead, they provide clinical context and guideline interpretations that inform the coverage determinations.

Coding and Billing

Not Reimbursed / Billing constraintsmixedNot Covered

Any AMA definitive drug class codes

Not reimbursed (policy states any AMA definitive drug class codes are not reimbursed)

Common presumptive and combined presumptive/confirmatory codesCPT

80305	Drug test(s), presumptive, any number of drug classes; direct optical observation (immunoassay), includes sample validation
80306	Drug test(s), presumptive; instrument assisted direct optical observation (immunoassay), includes sample validation
80307	Drug test(s), presumptive; by instrument chemistry analyzers, chromatography, and mass spectrometry, includes sample validation
0007U	Drug test(s), presumptive, with definitive confirmation of positive results, urine, includes specimen verification including DNA authentication

Definitive and proprietary test codesCPT | HCPCS

0011U	Prescription drug monitoring by LC-MS/MS, oral fluid, reported as comparison to estimated steady-state range
0051U	Prescription drug monitoring, LC-MS/MS, urine, 31 drug panel, quantitative
0079U	Comparative DNA analysis for specimen identity verification (ToxLok™)
0082U	Drug test(s), definitive, 90+ drugs, definitive chromatography with mass spectrometry, urine
0093U	Prescription drug monitoring, 65 common drugs by LC-MS/MS, urine
0227U	Chromatography with tandem mass spectrometry (LC-MS/MS) using MRM, includes sample validation (Proprietary tests listed)
0328U	Drug assay, definitive, 120+ drugs and metabolites, urine, quantitative LC-MS/MS
0517U	Therapeutic drug monitoring, 80+ psychoactive drugs, LC-MS/MS, plasma, qualitative and quantitative
0518U	Therapeutic drug monitoring, 90+ pain and mental health drugs, LC-MS/MS, plasma
0519U	Therapeutic drug monitoring specific to pain, depression, anxiety, LC-MS/MS, plasma, 110+ drugs

1–10 of 16

1/2

Applicable CPT/HCPCS Procedure Codes (definitive drug testing)HCPCS

G0483

Drug test(s), definitive, utilizing methods able to identify individual drugs and distinguish structural isomers (e.g., GC/MS, LC/MS), with stable isotope/internal standards, method/drug-specific calibration and matrix-matched QC; qualitative or quantitative; includes specimen validity testing; per day; 15-21 or 22+ drug classes depending on description.

G0659

Drug test(s), definitive, utilizing methods able to identify individual drugs and distinguish structural isomers (e.g., GC/MS, LC/MS), performed without method- or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s); qualitative or quantitative; includes specimen validity testing; per day; any number of drug classes.

Testing frequency thresholds for substance use treatment and opioid therapy monitoring

Presumptive testing frequency (opioid therapy, risk-stratified)Low risk: up to 1 test/year; Moderate risk: up to 2 tests/year; High risk: up to 4 tests/year; testing for aberrant behaviors allowed at time of visit.

Definitive testing frequency — SUD monitoring: 0-30 days abstinenceRandom definitive testing not to exceed 1 test per week.

Definitive testing frequency — SUD monitoring: 31-90 days abstinenceRandom definitive testing 1–3 tests per month; maximum 3 definitive tests in one month.

Definitive testing frequency — SUD monitoring: >90 days abstinenceDefinitive testing 1–3 tests every 3 months; maximum 3 definitive tests in a three-month period.

Provider Actions & Operational Guidance

Prior Authorization

Prior authorization — No explicit prior authorization requirements are specified in the references for outpatient presumptive or definitive drug testing. Reimbursement is contingent on meeting the policy's coverage criteria and documentation requirements; obtain any payer-specific prior authorization if separately required.

No payer-level prior authorization specified in referenced guidance — follow coverage criteria and documentation.
Check payer-specific portals for any separate prior authorization requirements.

Documentation Required

Confirm Positive Presumptive/POC Results with Definitive Testing

Confirm positives with definitive testing — Presumptive point-of-care (POC) and laboratory immunoassays have lower sensitivity and specificity than definitive methods. A positive presumptive result that will influence major clinical or nonclinical decisions should be confirmed using definitive testing (eg, GC‑MS, LC‑MS, LC‑MS/MS). Document the rationale for confirmatory testing in the medical record.

Definitions

DOA (Drugs of Abuse)

Definition of DOA (Drugs of Abuse)A drug, chemical, or plant product that is known to be misused for recreational purposes; includes prescription medications with misuse potential.

Common specimen typesUrine is the most commonly tested biological substance; other specimens include blood, hair, and saliva.

Clinical purposesTesting may be performed for compliance with treatment programs or medical regimens and to detect illicit or non-prescribed substances.

Presumptive vs Definitive testing

Presumptive (screening) vs Definitive (confirmatory)Presumptive testing: qualitative/semi-quantitative immunoassays that detect drug classes but cannot distinguish structural isomers; Definitive testing: chromatographic and mass spectrometric methods that identify specific drugs/metabolites and can be quantitative.

Level-of-Care Criteria

Outpatient / Substance use disorder monitoring

Level- and program-specific outpatient monitoring contexts where UDT is commonly applied:

Outpatient / Substance use disorder monitoring: Random qualitative testing per documented abstinence intervals is used for admission and ongoing monitoring in outpatient SUD treatment programs; frequency is highest early in treatment and decreases when stable.0–90 days: 1–2/week; >90 days: 1–3/month

Documentation of testing and results required in medical record.

Outpatient / Program-based monitoring: UDT can support admission decisions and ongoing monitoring for specialty programs (e.g., pain management clinics, OTPs) when baseline substance use status affects treatment planning.

Program policies and documentation expectations apply.

Outpatient/Chronic opioid therapy:

Testing Modalities & Methods

UDT/UDS (urine/oral fluid); definitive lab-based testing

Specimen types and general modalities for UDT and definitive testing:

UDT specimen types and modalities: Urine and oral fluid are covered specimen types for presumptive testing; blood/serum/plasma testing is appropriate in select clinical scenarios (e.g., anuric patients or when timing requires). Definitive laboratory-based testing (MS/GC-MS/LC-MS/MS) is used for confirmation and specific identification/quantitation.

Proprietary assays are not covered; choose specimen based on detection window and clinical question.

Definitive laboratory testing (GC-MS, LC-MS/MS)

Analytic methods for definitive testing:

Definitive analytic methods: Definitive laboratory testing employs chromatographic and mass spectrometric methods (e.g., GC-MS, LC-MS, LC-MS/MS) which are preferred for higher sensitivity and specificity and for detecting a broader range of compounds compared to immunoassays.

MS-based assays are the gold standard for confirmation and identification.

Frequency Limits & Visit-Based Thresholds

Definitive drug testing frequency (see thresholds)

Definitive testing frequency (SUD monitoring) — summaryMaximum numbers follow abstinence intervals: 0–30 days ≤1/week; 31–90 days 1–3/month (max 3/month); >90 days 1–3 every 3 months (max 3/3 months).

Context for limitsThese frequency maxima apply when definitive testing is used for diagnosing or monitoring individuals with substance use disorder per coverage criteria.

Relation to presumptive testingPresumptive screening frequencies for opioid therapy monitoring are lower and risk-stratified (see testing frequency thresholds).

Background and Evidence Summary

Drug testing is commonly used in outpatient settings—such as pain management, substance use treatment, and psychiatric care—to assess medication adherence, detect nonprescribed or illicit substances, and inform safety and treatment planning. Urine is the most frequently used specimen because of practical detection windows and convenience; definitive testing methods (e.g., GC‑MS, LC‑MS/MS) are preferred when specific identification or quantitation is required. The policy supports baseline testing and risk‑stratified monitoring when results will influence clinical management.

Policy Summary

PayerCapital Bluecross

PolicyPrescription Medication and Illicit Drug Testing in the Outpatient Setting

Policy CodePolicy AHS - T2015 - Prescription Medication and Illicit Drug Testing in the Outpatient Setting, 1 = Initial Presentation

Change TypeNo material change

Effective Date06/06/2015

Next Review DateN/A

Key ActionConfirm positive point-of-care or unexpected immunoassay results with definitive laboratory testing (GC/MS or LC-MS/MS) before making major clinical decisions.

SourceLink

On This Page

CDC, AACC, and specialty guidance recommend confirmatory testing in such situations.

Specimen selection and limitations: Urine is commonly preferred for cost and detection window; oral fluid and hair have different detection windows and strengths (e.g., hair may detect certain drugs like cocaine over longer periods; oral fluid may detect very recent use including 6-AM for heroin); consider serum/plasma in anuric patients.

Choice of specimen should reflect clinical question and detection window differences.

Limitations of quantitative testing for adherence assessment: Quantitative definitive urine testing should not be used solely to determine prescribed dosage adherence due to interindividual variability in pharmacokinetics and pharmacogenetics; quantitative testing may be useful for variant metabolism, impurities, or complex cases where concentration aids interpretation.

AACC and other reviews caution against using quantification for routine dose-adherence decisions.

Frequent random testing (at least weekly) initially in substance abuse treatment, decreasing to at least monthly when stable.

ASAM recommendations for SUD treatment monitoring.

ASIPP baseline and follow-up algorithm: Baseline POC immunoassay at initiation; random POC immunoassay at 1–3 months then 6–12 months if appropriate; unexplained/inappropriate results prompt confirmatory testing and repeat UDT in one month or at next appointment.

ASIPP algorithmic approach.

VA/DOD recommends urine drug testing for patients on long-term opioids as part of risk mitigation (weak recommendation).

Pregnancy and obstetric care: ACOG recommends validated verbal screening tools and notes routine universal urine drug screening is controversial; when UDT is performed it should be with informed consent and confirmatory testing when appropriate.

ACOG guidance.

Emergency evaluation for intoxication/overdose: WHO recommends urine drug screens in emergency cases when intoxication, withdrawal, or overdose is suspected, particularly if the patient cannot report ingestion.

WHO guidance.

Amphetamine immunoassay cutoff500 ng/mL (DRI® Amphetamines Assay).

Methamphetamine immunoassay cutoff1000 ng/mL (DRI® Amphetamines Assay).

Cocaine metabolite (benzoylecgonine) immunoassay cutoff150–300 ng/mL (DRI Cocaine Metabolite Assay; FDA-approved enzyme immunoassay).

PCP cutoff

PCP (phencyclidine) immunoassay cutoff25 ng/mL (qualitative screening assays report reactivity at 25 ng/mL).

Drug class coverage thresholds

G0480 — definitive test coverageDrug test(s), definitive, qualitative or quantitative — 1–7 drug classes (definition includes GC/MS or LC/MS methods).

G0482 — definitive test coverageDrug test(s), definitive — includes 15–21 drug classes as described in code definitions.

G0483 / G0659 — broader class/any-number definitionsG0483 described for 15–21 or 22+ drug classes depending on variant; G0659 may be billed for any number of classes with specific analytic caveats.

Number of drug classes

15–21 drug classesListed in code descriptors (e.g., G0483 may represent 15–21 drug classes).

22 or more drug classesListed in code descriptors (e.g., G0483 variant for 22+ drug classes).

Any number of drug classesG0659 description permits billing per day for any number of drug classes with stated analytic limitations.

POC positive results generally require confirmatory laboratory testing before definitive action.
Use definitive methods to confirm unexpected or clinically impactful results.
Document rationale for confirmatory testing in the patient's record.

Step Therapy

Definitive vs Presumptive Testing — Stepwise Preference

Definitive vs presumptive testing — Presumptive testing (immunoassay/EIA) is appropriate as an initial, rapid screen; definitive testing (GC‑MS, LC‑MS, LC‑MS/MS) is the most accurate method and is recommended for baseline assessment and ongoing monitoring in many chronic opioid/pain-management settings. Limit definitive testing to situations defined in the coverage criteria (eg, unexpected results, need to identify specific drugs, monitoring substance use disorder).

Presumptive testing: fast turnaround, lower sensitivity/specificity, suitable for initial screening or low‑risk monitoring.
Definitive testing: superior sensitivity and specificity; preferred for baseline and when results will affect management.
Restrict definitive testing to covered indications and document clinical rationale.

Note

Federal Testing Authorization Constraints

Federal testing authorization constraints — HHS rules for federal workplace programs require testing for specified analytes (eg, marijuana and cocaine for each specimen) and restrict routine additional drug or specimen‑validity testing by HHS‑certified labs without prior authorization. Additional analyses may be performed on a case‑by‑case basis (reasonable suspicion, post‑accident, or MRO request) but routine unsolicited expanded testing may not be authorized or reimbursed.

Federal HHS guidance requires specified analytes and limits routine additional testing without authorization.
Oral fluid panels are similarly constrained and additional validity testing requires case‑by‑case authorization.
Be aware testing beyond required analytes may need prior authorization in federal programs.

Billing Rule

Billing Codes Listed (Reference)

Billing codes listed — A range of presumptive and definitive CPT/HCPCS and proprietary codes are listed in the policy for reference. Procedure codes in the policy are for reference only and may not be all‑inclusive; verify coding and payer billing requirements prior to submission.

Presumptive codes: 80305, 80306, 80307, 0007U.
Definitive and proprietary/expanded panels: multiple U‑codes (e.g., 0051U, 0082U, 0093U, 0328U, 0517U–0520U) and G‑codes (G0480–G0483, G0659).
Procedure codes are included as general references; verify with payer coding guidance.

Denial Risk

Triggers for Denial / Common Denial Risks

Triggers for denial / denial risks — Certain uses are specifically not reimbursed: confirmatory/definitive testing for panels larger than seven drug classes, proprietary tests (eg, CareView360, NextGen Precision™), specimen validity testing, same‑day duplicate testing from different specimens, multiple presumptive tests per patient per date of service, and blanket/routine standing orders for all patients.

Definitive testing for >7 drug classes: not covered.
Proprietary tests and specimen validity testing: not covered.
Same‑day testing of same analyte from two different samples (eg, urine and blood): not reimbursed.
More than one presumptive test per patient per date of service and blanket orders: not reimbursed.

Documentation Required

Confirmatory Testing for Impactful Results

Confirmatory testing when results will affect management — National guidance (CDC, ACOG, AACC) emphasizes using confirmatory definitive testing (eg, GC‑MS, LC‑MS/MS) when results are unexpected or will inform decisions with major clinical or nonclinical implications, or when specific opioids/drugs within a class must be identified. Consider discussing possible confirmatory testing with the patient prior to ordering.

Use confirmatory testing for unexpected results that cannot be clinically explained.
Confirmatory testing is warranted when identification of specific drugs/metabolites will alter treatment or legal/administrative decisions.
Pre‑test discussion with the patient can sometimes obviate immediate confirmatory testing.

Documentation Required

Medical Record Documentation — Document Justification, Baseline and Follow‑up UDT

Documentation and medical‑record requirements — The patient's medical record must document medical necessity for testing (relevant history, physical exam, diagnostic results, PDMP query when applicable, and rationale for the type and frequency of testing). Confirmatory/definitive testing should be supported by documentation of rationale in the record.

Document: indication for testing, baseline and follow‑up UDT results, rationale for confirmatory testing, and how results guide management.
Include risk stratification, monitoring plan, and dates/frequency of follow‑up testing.
PDMP query and informed consent where required (eg, obstetric settings) should be documented.

Note

Baseline Testing, Algorithmic UDT Monitoring, and Baseline→Risk‑Based Follow‑Up

Baseline testing and risk‑based monitoring — Guidance supports baseline UDT prior to initiation of opioid therapy and an algorithmic, risk‑stratified monitoring approach: periodic monitoring to establish baseline, then low/medium/high risk frequencies (eg, at least annually for low risk; 2+ times/year for moderate; 3+ times/year for high risk), with additional tests as clinically indicated.

Perform baseline presumptive (POC or lab immunoassay) and consider definitive testing for baseline in many chronic pain patients.
Ongoing monitoring frequency should be based on risk stratification (low/moderate/high) per guideline recommendations.
Use an algorithmic approach: baseline → routine/random monitoring → confirmatory testing for unexpected or inconsistent results.

Documentation Required

Confirmatory Testing for Inconsistent POC/Immunoassay Results

Confirm inconsistent POC or immunoassay results — When point‑of‑care or laboratory immunoassay results are inconsistent with the clinical picture (history, presentation, or patient statement), perform definitive confirmatory testing. Do not rely solely on POC immunoassays when results are unexpected or would change management.

Unexpected negative for prescribed medication or unexpected positive for non‑prescribed/illicit drug: obtain definitive testing.
POC immunoassays have higher false‑positive/false‑negative risk — confirm before major decisions.

Documentation Required

Consent, Specimen Types, and Lab Test Characteristics

Consent, specimen types, and laboratory characteristics — Obtain and document patient consent where required (eg, prenatal care) and be aware of each laboratory's test characteristics. Only urine or oral fluid specimens are generally covered (blood only for anuric chronic renal failure per policy). Providers should consult laboratory package inserts or lab personnel to understand assay capabilities and limitations.

Follow state law and obtain consent in settings (eg, obstetrics) where required.
Covered specimen types: urine and oral fluid; blood covered only for anuric chronic renal failure.
Review lab test characteristics/package inserts and consult lab personnel for assay limitations.

Note

Technical Method Expectations for Definitive Testing

Technical method expectations — When definitive testing is performed, methods should meet accepted analytical standards: use GC‑MS or LC‑MS (or tandem MS) with stable isotope or recognized internal standards, method‑ or drug‑specific calibration, and matrix‑matched quality control materials as described in G‑codes and guidance. Documentation should support use of listed definitive methods.

G0480–G0483 and G0659 describe required analytic method characteristics (eg, GC/LC‑MS, internal standards, calibration, QC).
Definitive assays should identify individual drugs and distinguish structural isomers when required.
Document the analytic method used if definitive testing is billed.

Presumptive tests are used for initial screening; definitive tests are used to confirm positive or discordant results and when specific identification/quantitation is needed.

Relative performanceMS-based assays are considered the gold standard with higher sensitivity and specificity than immunoassays.

Presumptive

Presumptive testing — definitionQualitative or semi-quantitative assays (often immunoassays) used to detect the presence of a drug or drug class; do not distinguish structural isomers and may have cross-reactivity.

Typical formatsPoint-of-care devices and laboratory immunoassays (e.g., EIAs, EMIT) used for screening.

LimitationsVariable sensitivity and specificity; positive results often require confirmatory testing when clinically important.

Definitive

Definitive testing — definitionLaboratory methods using chromatography and spectrometry (e.g., GC, LC, tandem MS) that identify specific drugs and metabolites and may provide quantitative results.

When to useFor confirmation of unexpected or clinically impactful screening results, for SUD diagnosis/monitoring per abstinence frequency rules, and when precise concentrations guide management.

Examples of methodsGas chromatography (GC), liquid chromatography (LC), and mass spectrometry (MS/LC-MS/MS/GC-MS) are referenced as definitive techniques.

Definitive testing (e.g., GC-MS, LC-MS, LC-MS/MS)

Definitive analytic methodsGC-MS, LC-MS, and LC-MS/MS — analytic methods with higher sensitivity and specificity used to confirm specific drugs and metabolites.

Clinical preferenceMS-based assays are recommended as the most accurate method for baseline and ongoing monitoring in chronic pain patients unless immunoassay is required.

Role in confirmationDefinitive testing should confirm positive or discordant presumptive results before major clinical/legal decisions are made.

Presumptive (immunoassay) testing

Presumptive (immunoassay) testing — characteristicsQualitative point-of-care or laboratory immunoassays that screen classes of drugs; offer similar performance between POC and lab immunoassays but have assay-specific limitations and cross-reactivity.

Operational roleUsed as initial screening tools and for routine monitoring; package inserts and lab consultation recommended to interpret capabilities and limits.

Need for confirmatory testingPositive or unexpected results should be confirmed with definitive MS-based methods when results will affect major decisions.

Presumptive testing — note

Presumptive testing — additional notePOC qualitative immunoassays can detect many medications and illicit substances in pain management patients but require awareness of assay limitations.

RecommendationReference package inserts or consult laboratory personnel to prevent misinterpretation of immunoassay results.

Performance caveatsCertain drug classes (e.g., amphetamines, benzodiazepines, opiates) have notable immunoassay specificity issues.

Definitive testing — note

Definitive testing — additional noteDefinitive testing is preferred when precise identification or quantitation is needed; considered gold standard despite greater complexity and cost.

When mandatedUse definitive methods to resolve discrepant presumptive results or when clinical management depends on exact identification.

Guidance sourcesAACC and other specialty guidance emphasize definitive methods for monitoring and confirmation.

LDT

Laboratory-Developed Tests (LDTs)Tests developed and validated in-house by laboratories; regulated under CLIA '88 as high-complexity tests and not FDA-approved, though used clinically.

Regulatory contextLDTs are regulated by CMS under CLIA; FDA clearance/approval is not required for clinical use of LDTs in current practice.

Coverage cautionProprietary or certain LDT/proprietary platforms may be considered not covered per policy guidance.

Definitive drug testing (G0483, G0659)

G0483 — definitive drug testing code descriptionG0483: definitive drug test(s) using methods able to identify individual drugs and distinguish structural isomers (GC/MS, LC/MS), with internal standards and method/drug-specific calibration; described for 15–21 or 22+ drug classes depending on variant.

G0659 — definitive drug testing code descriptionG0659: definitive drug test(s) performed without method- or drug-specific calibration or matrix-matched QC or without use of stable isotope internal standards; qualitative or quantitative; per day; any number of drug classes.

Role in billing/definitionsCode definitions reference analytic methods and drug class groupings and set technical expectations for definitive testing reports.

mhGAP

mhGAP (WHO) referencemhGAP Intervention Guide — WHO resource for scaling up care for mental, neurological, and substance use disorders (listed in references).

UsefulnessReferenced as a guideline resource relevant to mental health and substance use disorder contexts where toxicology may be applied.

LocationIncluded in policy reference list of evidence-based scientific references.

Baseline urine testing prior to initiating opioid therapy is recommended; ongoing monitoring frequency should be stratified by risk (low/moderate/high) with random testing and confirmatory testing for unexpected results.

low: ≥1/yr; moderate: ≥2/yr; high: ≥3/yr

Follow institutional and payer rules for specific frequency limits.

Opioid Treatment Program / Substance Use Treatment: OTPs perform initial and routine POC screening with confirmatory testing as needed; SAMHSA requires testing at minimum for opioids, methadone, amphetamines, cocaine, and benzodiazepines prior to admission.

OTPs follow federal and state certification standards.

Inpatient / Emergency / Outpatient distinctions: UDT may be used across settings—emergency, inpatient, and outpatient—when clinical questions about intoxication, withdrawal, overdose, or treatment adherence arise; specimen choice and urgency influence method selection.

Use setting-appropriate assays and confirmatory testing when results will affect major decisions.

Outpatient / Program-based monitoring

Program-based monitoring contexts (e.g., psychiatric programs) where UDT may inform admission and ongoing care:

Admission to specialized programs: UDT can support admission decisions for drug treatment programs or pain management clinics when baseline substance use status affects treatment planning.

Documentation of baseline testing required.

Ongoing program monitoring: Periodic UDT may be used to monitor compliance and detect illicit use; algorithmic approaches with re-testing after noncompliance can improve adherence.

Studies show repeat testing can improve compliance in some cohorts.

Outpatient/Chronic opioid therapy

Chronic opioid therapy monitoring in outpatient settings:

Baseline testing prior to initiation: Baseline urine drug testing is recommended prior to initiating opioid therapy to identify unreported substance use and inform risk assessment.

Document baseline in the medical record per guidance.

Ongoing monitoring by risk: Ongoing toxicology monitoring frequency should be stratified by risk: low-risk at least annually, moderate-risk two or more times per year, high-risk three or more times per year; increase frequency as clinically indicated.frequency tiers per risk level

Argoff consensus and CDC recommend these risk-stratified frequencies.

Opioid Treatment Program / Substance Use Treatment

Opioid Treatment Program (OTP) and substance use treatment monitoring contexts:

OTP admission toxicology: SAMHSA requires testing at minimum for opioids, methadone, amphetamines, cocaine, and benzodiazepines prior to OTP admission; include other drugs based on local patterns or indications.

AATOD recommends addressing benzodiazepine use prior to OTP admission.

Ongoing OTP monitoring: ASAM recommends frequent random testing initially (at least weekly) with reduction to monthly testing when stable; confirmatory testing used for unexpected or clinically significant results.

Follow OTP regulatory and clinical guidance.

Inpatient / Emergency / Outpatient

Use of UDT across care settings for acute presentations and ongoing care:

Acute psych and emergency settings: Consider toxicology screening for acute psychosis or emergency presentations when substance exposure cannot be excluded; use testing when results will influence immediate management.

AACAP and WHO recommend testing when intoxication or overdose is suspected.

Inpatient and outpatient continuity: UDT may be applied in inpatient, emergency, and outpatient settings as clinically indicated, with specimen selection and analytic method chosen based on setting and clinical question.

Ensure timely confirmatory testing when results affect major decisions.

UDT (immunoassay and definitive testing)

Relationship between presumptive immunoassays and definitive testing:

Immunoassay screening and confirmation pathway: POC and laboratory immunoassays can be used for screening; however, due to limitations in sensitivity/specificity, unexpected or clinically important positive results should be confirmed with definitive MS-based testing. Laboratories and clinicians should consult package inserts and laboratory personnel regarding assay capabilities and limitations.

AACC recommends definitive testing when immunoassay results are inconsistent with clinical expectations.

Toxicology testing (POC immunoassay, GC/MS, LC-MS)

General toxicology testing modalities and usage considerations:

Toxicology testing modalities: Available modalities include point-of-care immunoassays (urine or oral fluid) for rapid screening and laboratory-based definitive tests (GC/MS, LC-MS/MS) for confirmation and specific identification/quantitation; select modality based on clinical question, setting, and need for definitive identification.

Refer to package inserts and laboratory expertise for limitations and cross-reactivity.

Urine Drug Testing (UDT) / Laboratory toxicology testing

UDT practice considerations for opioid therapy and broader psychiatric care:

UDT in opioid therapy and psychiatric care: UDT is recognized as a tool to detect misuse and monitor adherence in opioid therapy and may be used in psychiatric populations when substance use could affect diagnosis or treatment; definitive methods are emphasized when results guide significant clinical decisions.

VA/DOD and ACOG guidance highlight role and limitations; ensure informed consent and appropriate documentation.

General psychiatric treatments and guidelines

Guideline and evidence sources informing psychiatric and related recommendations:

Guideline sources: Specialty organizations (e.g., AACAP, WFSBP, NICE, AAN, VA/DOD, WHO, ACOG) provide condition-specific recommendations on when to use toxicology testing in psychiatric, neurologic, obstetric, and substance use disorder contexts.

Refer to cited guidelines for detailed condition-specific guidance and evidence summaries.